<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1088</ReferenceId>
        <DateLastUpdated>2017-02-27-08:00</DateLastUpdated>
        <Article>
            <PubmedId>15843542</PubmedId>
            <Abstract>Optimization of long term immunity depends on the functional persistence of memory T cells; however, there are no defined strategies for promoting memory T cell function and survival. In this study, we hypothesized that varying the strength of the recall stimulus could modulate the function and survival potential of memory CD4 T cells. We tested the ability of peptide variants of influenza hemagglutinin (HA) exhibiting strong and weak avidity for an HA-specific TCR, to modulate HA-specific memory CD4 T cells in vitro and in vivo. In vitro stimulation with a weak avidity peptide (L115) uncoupled memory CD4 T proliferation from effector cytokine production with low apoptosis, whereas stimulation with a strong avidity peptide (Y117) fully recalled memory T cell functions but triggered increased apoptosis. To determine how differential recall would affect memory T cells in vivo, we boosted BALB/c hosts of transferred, CFSE-labeled HA-specific memory CD4 T cells with native HA, Y117, and L115 variant peptides and found differences in early Ag-driven memory T cell proliferation and IL-7R expression, with subsequent changes in memory T cell yield. High avidity boosting resulted in rapid proliferation, extensive IL-7R down-regulation, and the lowest yield of HA-specific memory cells, whereas low avidity boosting triggered low in vivo proliferation, maintenance of IL-7R expression, and the highest memory T cell yield. Our results indicate that memory CD4 T cell function and survival can be modulated at the recall level, and can be optimized by low level stimulation that minimizes apoptosis and enhances responses to survival factors.</Abstract>
            <ArticleYear>2005</ArticleYear>
            <ArticlePages>5433-43</ArticlePages>
            <ArticleTitle>Modulation of memory CD4 T cell function and survival potential by altering the strength of the recall stimulus.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Patke</LastName>
                    <ForeName>Deepa S</ForeName>
                </Author>
                <Author>
                    <LastName>Farber</LastName>
                    <ForeName>Donna L</ForeName>
                </Author>
            </Authors>
            <Affiliations>Division of Transplantation, Department of Surgery, University of Maryland School of Medicine, Baltimore, MD 21201, USA.</Affiliations>
            <ArticleChemicalList>Epitopes, T-Lymphocyte;Hemagglutinin Glycoproteins, Influenza Virus;Ligands;Peptide Fragments;Receptors, Antigen, T-Cell</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; CD4-Positive T-Lymphocytes(cytology; immunology; metabolism); Cell Proliferation; Cell Survival(immunology); Epitopes, T-Lymphocyte(administration &amp; dosage; immunology; metabolism); Hemagglutinin Glycoproteins, Influenza Virus(administration &amp; dosage; immunology; metabolism); Immunization, Secondary(methods); Immunologic Memory(immunology); Ligands; Liver(cytology; immunology; metabolism); Lung(cytology; immunology; metabolism); Lymphocyte Activation(immunology); Lymphoid Tissue(cytology; immunology; metabolism); Mice; Mice, Inbred BALB C; Mice, Knockout; Mice, Transgenic; Peptide Fragments(administration &amp; dosage; immunology; metabolism); Receptors, Antigen, T-Cell(administration &amp; dosage; immunology; metabolism)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>174</Volume>
                <Issue>9</Issue>
                <Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
                <Issn>0022-1767</Issn>
                <MedlineTa>J Immunol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>HA 110</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>SFERFEIFPKE</LinearSequence>
                        <StartingPosition>127</StartingPosition>
                        <EndingPosition>137</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P28730.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11320</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 1</LocationOfData>
                <EpitopeId>57751</EpitopeId>
                <ReferenceStartingPosition>110</ReferenceStartingPosition>
                <ReferenceEndingPosition>120</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Altered peptide ligands with single mutations (Y117, with high avidity for the TCR, and  L115, with low avidity) were also assayed. Swiss-prot entry is for the Hemagglutinin precursor.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 1 and 3</LocationOfData>
                        <TCellId>15312</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000007</OrganismId>
                                <Age>8-16 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>No immunization</InVivoProcessType>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Na誰ve T cells from epitope specific-TCR transgenic animals were used as such or in vitro primed,  transferred to RAG-/- non transgenic animals, and collected 2 months later as memory CD4+ cells.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD4+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AssayedTcrMolecule>
                            <AssayedTcrMoleculeName>6.5</AssayedTcrMoleculeName>
                        </AssayedTcrMolecule>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                            <SourceOrganismId>10000000</SourceOrganismId>
                            <Sex>F</Sex>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>170</MhcAlleleId>
                            <MhcEvidenceCode>T cell assay -T cell subset identification</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HA 110</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SFERFEIFPKE</LinearSequence>
                                        <StartingPosition>127</StartingPosition>
                                        <EndingPosition>137</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P28730.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11320</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>577</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Both na誰ve and memory CD4+ epitope-specific-TCR-transgenic cells respond to this antigen in the entire dose range (0.5-50 microgram/ml) assayed. Responses to low avidity APL (L115) are 40% lower at a low (0.5 microgram/ml) concentration, while responses to high avidity APL (Y117) are 40% lower at a high (50 microgram/ml) concentration of peptide. This latter effect correlates with increased apoptosis in high avidity APL stimulated cells and not to downregulation of TCR. In vivo recall proliferation of memory CD4 cells following peptide immunization is lower for L115 than for the natural epitope, but IL7-R downregulation is lower, implying a higher survival capacity. Consequently, higher memory CD4+ cell yields are obtained and IFN-g and IL-2 producing cells are higher in L115  than in natural or Y117 boosted mice, implying the memory cells are able to redifferentiate into functionally competent effector cells more effectively with the low avidity APL.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 6 and 7, table II</LocationOfData>
                        <TCellId>15326</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000007</OrganismId>
                                <Age>8-16 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>No immunization</InVivoProcessType>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Na誰ve T cells from epitope specific-TCR transgenic animals were used as such or in vitro primed,  transferred to RAG-/- non transgenic animals, and collected 2 months later as memory CD4+ cells.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD4+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AssayedTcrMolecule>
                            <AssayedTcrMoleculeName>6.5</AssayedTcrMoleculeName>
                        </AssayedTcrMolecule>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                            <SourceOrganismId>10000000</SourceOrganismId>
                            <Sex>F</Sex>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>170</MhcAlleleId>
                            <MhcEvidenceCode>T cell assay -T cell subset identification</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HA 110</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SFERFEIFPKE</LinearSequence>
                                        <StartingPosition>127</StartingPosition>
                                        <EndingPosition>137</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P28730.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11320</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Both na誰ve and memory CD4+ epitope-specific-TCR-transgenic cells respond to this antigen in  the entire dose range (0.5-50 microgram/ml) assayed, with peak responses at 48hs of culture with peptide loaded APCs. By contrast, recall responses to low avidity APL (L115) are low at any concentration and similar low levels of IL-4 are seen, implying that lower avidity stimulation of memory cells does not induce a shift in the cytokine secretion profile, but results in functional uncoupling of proliferation from cytokine production.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

